ABSTRACT
The viral accessory protein Vpx is required for productive in vitro infection of macrophages by simian immunodeficiency virus from sooty mangabey monkeys (SIV(SM)). To evaluate the roles of Vpx and macrophage infection in vivo, we inoculated pigtailed macaques intravenously or intrarectally with the molecularly cloned, macrophage tropic, acutely pathogenic virus SIV(SM) PBj 6.6, or accessory gene deletion mutants (deltaVpr or deltaVpx) of this virus. Both wild-type and SIV(SM) PBj deltaVpx viruses were readily transmitted across the rectal mucosa. A subsequent 'stepwise' process of local amplification of infection and dissemination was observed for wild-type virus, but not for SIV(SM) PBj deltaVpx, which also showed considerable impairment of the overall kinetics and extent of its replication. In animals co-inoculated with equivalent amounts of wild-type and SIV(SM) Pbj deltaVpx intravenously or intrarectally, the deltaVpx mutant was at a strong competitive disadvantage. Vpx-dependent viral amplification at local sites of initial infection, perhaps through a macrophage-dependent mechanism, may be a prerequisite for efficient dissemination of infection and pathogenic consequences after exposure through either mucosal or intravenous routes.
Subject(s)
Macrophages/immunology , Macrophages/virology , Simian Immunodeficiency Virus/pathogenicity , Viral Regulatory and Accessory Proteins/physiology , Animals , Cercocebus atys , Genotype , Immunohistochemistry , In Situ Hybridization , Intestinal Mucosa/virology , Macaca nemestrina , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/physiology , Viral Load , Virus ReplicationABSTRACT
Studies of primate lentivirus phylogeny over the past decade have established a minimum of five related, but genetically distinct, groups of simian immunodeficiency virus (SIV), each originating from a different African primate species. The hypothesis that HIV-2 (and SIVmac) arose by cross-species transmission from sooty mangabeys (Cercocebus atys has been strengthened by a more detailed characterization of the SIVsm/SIVmac/HIV-2 group of viruses. SIV from all four subspecies of African green monkeys (SIVagm) have been characterized with an apparent chimeric genome structure of SIVagm from West African green monkeys. Although these naturally infected primates remain healthy, cross-species transmission to other primate species may result in immunodeficiency, as caused by SIVsm infection of macaque monkeys (Macaca sp.) and recently, SIVagm infection of pig-tailed macaques (M. nemestrina). Studies of variation within infected individuals have been facilitated by adaptation of the techniques of heteroduplex analysis and single-stranded conformational polymorphism of PCR generated fragments.
Subject(s)
HIV/genetics , Lentivirus/genetics , Lentivirus/physiology , Phylogeny , Simian Immunodeficiency Virus/genetics , Africa , Amino Acid Sequence , Animals , Chimera , Chlorocebus aethiops , Genetic Variation , Genome, Viral , HIV/classification , HIV/physiology , HIV Long Terminal Repeat , HIV-2/genetics , Humans , Lentivirus/classification , Lymphocytes/virology , Molecular Sequence Data , Primates , Repetitive Sequences, Nucleic Acid , Sequence Homology, Amino Acid , Simian Acquired Immunodeficiency Syndrome/physiopathology , Simian Immunodeficiency Virus/classification , Simian Immunodeficiency Virus/physiology , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/geneticsABSTRACT
Over the past decade, a substantial research investment has generated a vast body of knowledge relevant to the development of an effective AIDS vaccine. Furthermore, studies in nonhuman primates have demonstrated that a number of candidate immunogens can confer a significant degree of protection against a potentially pathogenic SIV or SHIV. Currently, there exists a robust program that supports discovery of new HIV immunogens and a proven successful program for collaborative human trials of promising vaccine candidates. However, we believe that there is a gap between discovery and clinical trials. An orderly process for screening of candidate immunogens prior to human trials would facilitate the vaccine development program. We suggest that nonhuman primates can fill this strategic gap and could accelerate vaccine development. Recognizing that there is considerable controversy about the potential usefulness of the primate models, we have attempted to set forth the relevant practical and biological issues as a series of questions for discussion. The most important biological problem is the absence of a single immune response correlate that will predict vaccine efficacy. Data from primate models indicate that such a single predictive correlate may not exist. In turn, this argues for a vaccine screening protocol that includes a pathogenic virus challenge, an approach only available in the nonhuman primate model. The further assumption is that nonprimate models can be used to predict the relative protective efficacy of diverse immunization protocols, a hypothesis that can only be tested by comparative studies yet to be conducted. A 'standard' set of virus challenges must be selected for comparison of different immunization protocols, and this effort has been initiated. At the practical level, it appears that the large number of candidate immunogens now being developed requires a screening process of the kind proposed, since it would not be practical to test all new immunogens and protocols in humans. In conclusion, it appears timely to crystallize an orderly process for the discovery, screening, and human testing of candidate AIDS vaccines, understanding that a vaccine development program should not be conducted at the expense of investigator-initiated research in the diverse disciplines that support rational vaccine design and development. The components of a rational process of vaccine development are well established and only remain to be welded into one coherent program.
Subject(s)
AIDS Vaccines/therapeutic use , Disease Models, Animal , Primates , AIDS Vaccines/administration & dosage , AIDS Vaccines/immunology , Animals , HumansABSTRACT
OBJECTIVE: An in-frame stop codon prematurely truncating the transmembrane glycoprotein (TMP) is a common feature of many simian immunodeficiency virus, African green monkey strain (SIVagm) molecular clones. The purpose of this study was to investigate the native form of the SIVagm TMP in a naturally infected African green monkey (AGM) and to study the fate of the stop codon following the passage of SIVagm in primates. DESIGN: Polymerase chain reaction was used to clone the entire intracellular portion of the TMP from: (1) peripheral blood mononuclear cells (PBMC) of the naturally infected AGM 155; (2) an isolate of SIVagm155 in rhesus PBMC and (3) PBMC from pig-tailed macaques and AGM experimentally infected with an SIVagm molecular clone encoding a truncated TMP. RESULTS: PBMC of the naturally infected AGM contained a 'swarm' of related virus genotypes that encoded a full-length TMP, whereas tissue-culture passage in rhesus PBMC resulted in a prematurely truncated form of the TMP. This premature stop codon persisted in PBMC of monkeys experimentally infected with an SIVagm molecular clone. Both macaques and AGM of same subspecies as AGM 155 (Cercopithecus pygerythrus) and other subspecies (C. aethiops and C. sabaeus) became infected with SIVagm155. Genetic drift of this region of env, as assessed by calculation of the nucleotide substitution/site/year rate, was similar to that of other retroviruses. CONCLUSIONS: The native form of the SIVagm TMP is a full-length gp40, similar to the SIV macaque (SIVmac) strain and HIV-1. However, passage of SIVagm in tissue culture can result in point mutations that introduce a premature stop codon. This stop codon persists during subsequent in vivo passage of SIVagm in primates. This contrasts with similar studies in macaques infected with SIVmac, in which reversion of the TMP stop codon was observed.
Subject(s)
Gene Products, env/genetics , Genetic Variation , Retroviridae Proteins, Oncogenic/genetics , Simian Immunodeficiency Virus/genetics , Viral Fusion Proteins , Amino Acid Sequence , Animals , Base Sequence , Chlorocebus aethiops , Cloning, Molecular , Codon , DNA Primers , Humans , Macaca mulatta , Macaca nemestrina , Molecular Sequence Data , Polymerase Chain Reaction , Sequence Homology, Amino Acid , Simian Immunodeficiency Virus/classification , Terminator Regions, GeneticABSTRACT
We tested three commercially available HIV-1 antigen capture systems for their ability to detect simian immunodeficiency viruses (SIV). All three kits detected antigens from six distinct SIV isolates, but with varying degrees of sensitivity. For the overall detection of SIV in cell culture, our assay for reverse transcriptase was more sensitive than HIV-1 antigen capture. HIV-1 antigen capture systems were useful for the detection of SIV antigenemia in experimentally infected macaques. The limited sensitivity of HIV-1-specific antigen capture suggests that SIV-specific antigen capture reagents should be developed.
Subject(s)
Antigens, Viral/analysis , HIV Antigens/immunology , HIV-1/immunology , Simian Immunodeficiency Virus/immunology , Animals , Humans , Immunoenzyme Techniques , Macaca mulatta , Predictive Value of Tests , RNA-Directed DNA Polymerase/analysis , Reagent Kits, Diagnostic , Simian Immunodeficiency Virus/isolation & purificationABSTRACT
The SIV family is a diverse group of viruses that vary considerably in pathogenesis and virulence in their natural host species or macaques. Although the disease induced by the SIVsm subtype in particular is remarkably similar to human AIDS, it must be remembered that this is an experimental animal model. Therefore, although the pathogenesis of SIVsm (and other viruses) in macaques offers an relevant animal model for pathogenesis and vaccine trials, the interactions of these viruses in their natural host, and virus-, or host-specific effects have been poorly characterized. This animal model offers a unique opportunity to study the details of the pathogenesis of immunodeficiency and to define host and viral factors responsible for disease progression.
Subject(s)
Simian Immunodeficiency Virus/pathogenicity , Acquired Immunodeficiency Syndrome/etiology , Animals , DNA, Viral/genetics , Disease Models, Animal , Genetic Variation , Humans , Macaca , Phylogeny , Simian Acquired Immunodeficiency Syndrome/etiology , Simian Immunodeficiency Virus/classification , Simian Immunodeficiency Virus/genetics , Virulence/geneticsABSTRACT
One of the major questions in AIDS is the role that the host immune system and the virus play in the dynamics of infection and the development of AIDS in an infected individual. In order to test the role of antibody in controlling viral infection, high-dose SIV-immune globulin was passively transferred to infected macaques early in infection. Immune globulin purified from the plasma of an SIV-infected long-term non-progressor macaque (SIVIG) or a pool of normal immune globulin (normal Ig) was infused into SIVsmE660-infected macaques (170 mg/kg) at one and fourteen days post infection. Animals were monitored for SIV-specific antibodies, viremia, plasma antigenemia, and clinical course. All animals were infected by SIV. At 16 months post infection, five macaques in the combined control groups have been euthanized, one as a rapid progressor with debilitating disease at 20 weeks post infection. Four macaques from the comparison groups have signs of AIDS, accompanied by high and increasing levels of virus and p27 antigenemia. One of the ten control animals had a very low virus load in plasma and peripheral blood and lymph node mononuclear cells at all times tested and has remained disease-free. In the SIVIG treatment group, two macaques were euthanized at 18-20 weeks due to AIDS, rapid progressors to disease. Three macaques in the SIVIG group had an initial high level of virus in plasma, peripheral blood mononuclear cells (PBMC), and lymph node mononuclear cells (LNMC), which dropped to baseline at 6 weeks post infection and has remained very low or negative for 16 months, a disease profile which has not been observed in untreated animals in this model to date. These macaques have remained clinically healthy. The sixth treated animal is also healthy, with very low virus burden that is detectable only by nested set polymerase chain reaction (PCR). All SIVIG-treated macaques had no detectable p27 plasma antigenemia for the first 10 weeks of infection, demonstrating that the IgG effectively complexed with the virus. The immunological correlates in the treated animals include development of de novo virus-specific antibodies and/or cytotoxic T cell (CTL), both of which are hallmarks of long term non-progressors. The two SIVIG-treated macaques that progress to disease rapidly had no detectable de novo humoral immune responses, as is often seen in rapid HIV disease in humans. Envelope-specific and virus neutralizing antibodies alone were not sufficient to prevent disease progression, as the plasma of both non-progressors as well as progressors had high titers of envelope-specific and neutralizing antibodies against SIVsmE660. Poor clinical prognosis was associated with moderate to high and increasing virus loads in plasma, PBMC, and lymph nodes. Good clinical prognosis correlated with low or undetectable post acute viremia in the peripheral blood and lymph nodes. We hypothesize that SIVIG reduced the spread of virus by eliminating or reducing plasma virus through immune complexes during the first four to 8 weeks of infection and then maintaining this low level of viremia until the host immune response was capable of virus control. Reduction of virus burden early in infection by passive IgG can alter disease outcome in SIV infection of macaques. Modifications of this strategy may lead to effective early treatment of HIV-1 infection in humans.
Subject(s)
Antibodies, Viral/immunology , Immunization, Passive , Immunoglobulins, Intravenous/therapeutic use , Simian Acquired Immunodeficiency Syndrome/therapy , Simian Immunodeficiency Virus/immunology , Animals , Antibodies, Viral/administration & dosage , Disease Progression , Drug Administration Schedule , Macaca mulatta , Prognosis , Simian Acquired Immunodeficiency Syndrome/etiology , Simian Acquired Immunodeficiency Syndrome/immunologyABSTRACT
Diversity in the peripheral T cell receptor repertoire of rhesus (Macaca mulatta) and pig-tailed macaques (Macaca nemestrina) has been studied by examining the profile of CDR3 lengths in TCR beta chains. Expressed CDR3 length distribution profiles for individual TCRBV families were obtained from total peripheral blood mononuclear cells (PBMC) and T cell subsets isolated from PBMC. These studies reveal that the T cell receptor repertoire of PBMC from healthy macaques often exhibits skewing in TCRBV family CDR3 profiles. The skewing of TCRBV family CDR3 profiles was evident as discrete expanded length(s) and was detected in up to 50% of the PBMC profiles. Analyses of separated T cell populations demonstrated that the CD8+ T cell subset was responsible for the majority of observed skewing in CDR3 length profiles. However, CD4+ T cells were also shown to contribute to the skewed peripheral PBMC repertoire in these animals. While certain TCRBV families frequently displayed skewed profiles, there was no concordance in the particular CDR3 lengths expanded among the different animals. Furthermore, an additional feature of the peripheral blood of the animals studied was the presence of an unusual population of extrathymic CD4 and CD8+ (double-positive) T cells (up to 9.6% in the PBMC of rhesus macaques). The double-positive T cells could be differentiated from CD4 single-positive and CD8 single-positive T cells by their increased surface expression of LFA-1 and decreased CD62L expression. The percentage of the double-positive T cells was higher in rhesus than pig-tailed macaques and contributed substantially to the peripheral T cell repertoire.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor , Macaca/immunology , Receptors, Antigen, T-Cell, alpha-beta/genetics , Animals , CD4-CD8 Ratio , DNA Primers , DNA, Complementary/genetics , Macaca/genetics , Macaca mulatta/genetics , Macaca mulatta/immunology , Macaca nemestrina/genetics , Macaca nemestrina/immunology , Polymerase Chain Reaction , Reference Standards , Reproducibility of ResultsABSTRACT
Differences in kinetics of infection, cellular tropism, and cytopathology of SIV and HIV appear to depend on both viral and host factors. We investigated the role of critical CD4 structures from African green monkeys (AGM) a natural SIV host, from pig-tailed macaques (PT) an unnatural SIV host, and from humans, as well as the role of species-specific cellular factors involved in the tropism, kinetics of infection, and cytopathic effects of several SIV and HIV-1. Critical regions of the PT macaque and AGM CD4 genes (V1, V1J1, and V1J1V2J2) were stably expressed as chimeras with the human CD4 gene in human (HeLa and 293) and macaque (CMMT) cell lines. CD4 expressing cell lines were used for infection studies with cell-free SIVsm, SIVmac, SIVsmmPBj, SIVagm, and HIV-1. Results show that both PT CD4 and AGM CD4 supported infection with comparable infection kinetics by all SIV or HIV-1 strains tested. Although structural analysis predicted a major change in secondary structure of AGM CD4/CDR-3, these structural changes did not influence the degree of syncytia formation induced by several SIV and HIV-1. However, the cell line used to express the CD4 gene appeared to be a critical determinant of infection. Thus, SlV strains did not infect human cell lines regardless of the CD4 expressed in these cells. In contrast, HIV-1 did not infect any macaque cell line. This study demonstrates that the differences in CD4 structure among different primate species are clearly not responsible for differences in SIV and HIV infection kinetics, tropism, and cytopathology. However, species-specific factor(s), presumably expressed on the cell surface, markedly influences the ability of SIV or HIV to infect cells expressing CD4.
Subject(s)
CD4 Antigens/chemistry , CD4 Antigens/metabolism , HIV-1/metabolism , Receptors, Immunologic/physiology , Simian Immunodeficiency Virus/metabolism , Amino Acid Sequence , Animals , CD4 Antigens/genetics , Cell Line , Chlorocebus aethiops , Giant Cells/virology , HIV Infections/virology , HIV-1/pathogenicity , HeLa Cells , Humans , Macaca nemestrina , Molecular Sequence Data , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/immunology , Sequence Homology, Amino Acid , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/pathogenicityABSTRACT
Simian immunodeficiency virus (SIV) infection of macaques is the best available animal model for studying the pathogenesis of AIDS. Experimental inoculation of macaques with SIV results in a persistent infection that leads to immunodeficiency, opportunistic infections, and death. Most aspects of the illness, including immunologic and virologic parameters, are easily quantified. Furthermore, pathologic processes can be evaluated throughout the course of experimental infection. Recently, molecular clones of SIV proviral DNA have been used to study genetic variation and specific viral determinants of pathogenesis. Considered together, these observations support the continued detailed study of SIV infection of macaques as a model for human AIDS.
Subject(s)
Acquired Immunodeficiency Syndrome/etiology , Disease Models, Animal , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/etiology , Animals , Chimera/genetics , Cloning, Molecular , Genetic Variation/genetics , Molecular Biology , Simian Immunodeficiency Virus/geneticsABSTRACT
The generation of biologically active proviral DNA clones of simian immunodeficiency virus (SIV) that give rise to infectious virions has allowed the detailed examination of genetic variation in experimentally inoculated monkeys. Studies of nucleotide sequences derived directly from circulating leukocytes of infected monkeys show that the SIV genome undergoes rapid and dramatic variation during the course of infection. The env gene is a major site for variation, and within the Env protein, hypervariable regions analogous to those previously defined for the human immunodeficiency virus type 1 (HIV-1) env gene are apparent. A major exception is the region corresponding to the V3 domain in HIV-1, which has been highly conserved in all SIV studies to date. These data notwithstanding, the role of SIV genetic variation in the pathogenesis of AIDS in monkeys remains unclear. Genetic variation within the env gene does not appear to be sufficient for the development of AIDS since significant variation is observed in both pathogenic and nonpathogenic SIV infections. Furthermore, although it generally is believed that env gene variation might allow HIV and SIV to avoid recognition and elimination by host immune responses, this premise has not been rigorously proven. The use of molecularly cloned SIV in monkey models has provided important quantitative and qualitative information on in vivo sequence variation, and these data, in turn, have laid the groundwork for addressing the undoubtedly complex functional significance of this variation.
Subject(s)
Genetic Variation/genetics , Simian Immunodeficiency Virus/genetics , Amino Acid Sequence , Animals , Cloning, Molecular , Genes, env/genetics , Haplorhini , Molecular Sequence Data , Nucleotides/genetics , Simian Acquired Immunodeficiency Syndrome/microbiologyABSTRACT
Internally controlled RT-PCR methods (QC-RT-PCR) for quantification of SIV RNA are effective, but are relatively cumbersome, expensive, and time and labor intensive. For greater throughput and efficiency, we have developed a method for quantification of plasma SIV RNA levels by real-time RT-PCR using the Applied Biosystems Prism 7700 sequence detection system. This assay format allows real-time kinetic analysis of PCR product generation, providing a broad linear dynamic range and ensuring that quantification is based on analysis during the exponential phase of amplification, regardless of the input template copy number. Simultaneous amplification and analysis eliminates any requirement for handling amplified products, increasing throughput and eliminating a potential source of assay contamination. The assay we have developed for quantification of SIV RNA has a nominal threshold sensitivity of 300 copy Eq/ml of plasma, although as little as 10 copy Eq/reaction of SIV RNA template can be detected. The linear dynamic range is in excess of 5 logs. Interassay reproducibility averages 25% (coefficient of variation), based on studies of extraction and analysis of replicate aliquots of the same plasma specimens. The combination of sensitivity, precision, and broad dynamic range allows reliable quantification of viral load even during dynamic phases of SIV infection, such as through the onset and resolution of primary infection, or during treatment with antiretroviral agents. The primer-probe combinations we have developed allow quantification of SIV isolates most commonly used for experimental studies. Availability of this assay should greatly facilitate studies of basic pathogenesis and evaluation of therapeutic and prophylactic approaches in the SIV-infected macaque.
Subject(s)
Polymerase Chain Reaction/methods , RNA, Viral/blood , Simian Immunodeficiency Virus/isolation & purification , Viral Load , Animals , RNA-Directed DNA Polymerase , Simian Immunodeficiency Virus/geneticsABSTRACT
A macaque CD4 + adherent cell line was generated by stable expression of the human CD4 gene in a rhesus macaque mammary tumor cell line, CMMT. The resulting cell line CMMT/CD4 expressed surface CD4 and was sensitive to infection by a wide range of isolates of simian immunodeficiency virus (SIV) of different subgroups, but was not susceptible to infection with HIV-1. The CMMT/CD4 cell line was used to develop a microassay for measurement of neutralizing antibody in plasma of SIV-infected or immunized animals. Single infected cells could be detected in a monolayer of CMMT/CD4 by immunoperoxidase and a 90% reduction in the number of positive cells was used as a measure of neutralizing activity of two-fold plasma dilutions. This assay had comparable sensitivity to methods based upon detecting a reduction in reverse transcriptase activity of SIV, reduction of viral antigen, or inhibition of cytopathic effect.
Subject(s)
Antibodies, Viral/blood , CD4 Antigens/biosynthesis , Simian Immunodeficiency Virus/pathogenicity , Tumor Cells, Cultured/virology , Animals , Antibodies, Viral/immunology , CD4 Antigens/genetics , CD4 Antigens/immunology , Cell Adhesion , Cytopathogenic Effect, Viral , HIV-1/pathogenicity , Humans , Macaca mulatta , Neutralization Tests , Simian Immunodeficiency Virus/immunology , Transfection , Tumor Cells, Cultured/immunologyABSTRACT
Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-Fha/np induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA-SIVenv/gag/pol greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-beta gal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.
Subject(s)
Genetic Vectors , Vaccines, Synthetic , Vaccinia virus , Viral Vaccines , Animals , Colonic Neoplasms/immunology , Colonic Neoplasms/prevention & control , Humans , Influenza Vaccines , Neoplasms, Experimental/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus , Transfection , Vaccinia virus/physiology , Virus ReplicationABSTRACT
A hereditary anomaly of neutrophil granulation in purebred Birman cats was described with respect to genetic, electron microscopic, histochemical, and functional characters. The trait was inherited in an autosomal recessive manner and was prevalent in the population studied. Affected cats had fine eosinophilic granules in the cytoplasm of neutrophils. The granules had normal morphology as determined by electron microscopy and did not stain for acid mucopolysaccharide. Bactericidal activity, phagocytosis, and oxidative function of affected neutrophils were not different from those of unaffected neutrophils. The anomaly was concluded to be an alteration in the content of lysosomal granules with increased affinity for acidic dyes.
Subject(s)
Cat Diseases/genetics , Hematologic Diseases/veterinary , Neutrophils/pathology , Animals , Azure Stains , Blood Bactericidal Activity , Bone Marrow/pathology , Cat Diseases/pathology , Cats , Cattle , Cytoplasmic Granules/ultrastructure , Female , Genes, Recessive , Hematologic Diseases/genetics , Hematologic Diseases/pathology , Male , Microscopy, Electron , Neutrophils/ultrastructure , PedigreeABSTRACT
Suppurative cholangitis in 5 aged cats was characterized clinically by weight loss, depression, dehydration, icterus, and fever. The major abnormal laboratory findings were a severe left shift of WBC and a high, conjugated bilirubin concentration consistent with an inflammatory process and cholestasis. Gross pathologic findings included periductal biliary fibrosis (4 cats), periductal pancreatic fibrosis (2 cats), cholelithiasis (2 cats), deformation of the gallbladder (2 cats), and chronic interstitial pancreatitis (2 cats). Histopathologic findings in all cases were portal hepatic fibrosis, biliary hyperplasia, and suppurative exudate within dilated intrahepatic biliary ducts. Weight loss and portal fibrosis were suggestive of chronic, intermittent illness. The pathogenesis appeared to involve invasion of the bile duct by enteric bacteria. Cholangitis was observed to occur in association with pancreatitis, cholelithiasis, or anatomic abnormalities of the biliary tract.
Subject(s)
Cat Diseases/pathology , Cholangitis/veterinary , Animals , Cat Diseases/etiology , Cats , Cholangitis/etiology , Cholangitis/pathology , Male , SuppurationABSTRACT
As presented in this review, there are a number of different models of both natural and experimental infection of monkeys with primate lentiviruses. There are numerous different viruses and multiple different monkey species, making for a potentially large number of different combinations. The fact that each different combination of virus isolate and host macaque species may show different behavior underscores the need to understand the different models and their key features. On the one hand, this diversity of systems underscores the need to provide some standardization of the systems used for certain kinds of studies, such as vaccine evaluations, in order to facilitate the comparison of results obtained in different experiments, but in essentially the same experimental system. On the other hand, the rich diversity of different systems, with different features and behaviors, represents a tremendous resource, among other things allowing the investigator to select the system that best recapitulates particular aspects of human HIV infection for study in a relevant nonhuman primate model. Such studies have provided, and may be expected to continue to provide, important insights to guide HIV treatment and vaccine development in the future.
Subject(s)
Acquired Immunodeficiency Syndrome/etiology , Disease Models, Animal , Simian Acquired Immunodeficiency Syndrome/etiology , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/prevention & control , Animals , Anti-HIV Agents/therapeutic use , Humans , Polymerase Chain Reaction , RNA, Viral/analysis , SAIDS Vaccines/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/isolation & purification , Simian Immunodeficiency Virus/physiology , Vaccines, DNA/immunology , Virus ReplicationABSTRACT
The clinical, laboratory, radiographic and pathological findings of two dogs with similar neoplasms are described. Both dogs were mature males of a large breed and had pleural and abdominal effusions containing neoplastic cells. Diffuse scirrhous thickening of the pleura and serosal surfaces was a prominent feature. A fibrous layer containing nests of neoplastic, epithelial-like cells was present on serosal surfaces. The morphological appearance of the cells was suggestive of either an atypical sclerosing mesothelioma or a scirrhous carcinoma. On the basis of ultrastructural and differential staining characteristics, a diagnosis of a scirrhous carcinoma of undetermined primary origin was made in one case and of prostatic urethral origin in the other case.
Subject(s)
Abdominal Neoplasms/veterinary , Adenocarcinoma, Scirrhous/veterinary , Dog Diseases/diagnosis , Mesothelioma/veterinary , Abdominal Neoplasms/diagnosis , Adenocarcinoma, Scirrhous/diagnosis , Animals , Diagnosis, Differential , Dogs , Male , Mesothelioma/diagnosisABSTRACT
A retrospective study of bovine peritoneal fluids collected over a two year period was conducted. Of a total of 66 cattle studied, 31 had a nonseptic peritonitis, 11 acute bacterial peritonitis, eight ascites and 16 miscellaneous disorders such as abomasal impaction, enteritis and lymphosarcoma. Peritoneal fluid analysis was a useful aid in the diagnosis of abdominal disorders of cattle, especially as hematological changes were absent in many cases. Due to relatively low nucleated cell counts in bovine peritonitis, all parameters (i.e. nucleated cell count, total protein and differential cell counts) must be evaluated before interpretation. A nucleated cell count of greater than 6000 cells/muL and total protein content of greater than 3 g/dL was consistent with the diagnosis of peritoneal inflammation in 80% of the cases studied. An atlas of cell types common to bovine peritoneal fluid is presented.